Zanidatamab: all 26 studies that test it
Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsNot yet recruitingNCT07841873Phase 2
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingNCT07745296Phase 3
- An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard TherapyNot yet recruitingNCT07631871Phase 2
- Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent TreatmentRecruitingNCT07405476Phase 2
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBCRecruitingNCT07296705Phase 2
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasRecruitingNCT07290985Phase 2
- Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.RecruitingNCT07192068Phase 2
- Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingNCT07176312Phase 2
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingNCT06695845Phase 2
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingNCT06435429Phase 3
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 3
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaRecruitingNCT06043427Phase 2
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)RecruitingNCT05035836Phase 2
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- ZW25 in Women With Endometrial CancersCompletedNCT04513665Phase 2Results posted
- A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersCompletedNCT04466891Phase 2Results posted
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results posted
- Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella TrialStatus unknownNCT05270889Phase 2
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3
- A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerCompletedNCT05027139Phase 1/2
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerCompletedNCT03929666Phase 2
- Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersCompletedNCT02892123Phase 1